Overview of anti-angiogenic agents in development for ovarian cancer (Q37826911)

23 August 2017

1 reference

title

Overview of anti-angiogenic agents in development for ovarian cancer (English)

1 reference

23 August 2017

1 reference

angiogenesis inhibitor

1 reference

Robert A Burger

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

8 January 2011

1 reference

23 August 2017

1 reference

23 August 2017

volume

121

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

230-238

1 reference

23 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Induction of angiogenesis during the transition from hyperplasia to neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Angiogenesis in cancer and other diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Angiogenesis as a therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Angiogenesis in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Angiogenesis in normal and neoplastic ovaries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Antiangiogenic drugs in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

VEGFs and receptors involved in angiogenesis versus lymphangiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

VEGF-targeted therapy: mechanisms of anti-tumour activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

What brings pericytes to tumor vessels?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Human microvascular endothelial cells express receptors for platelet-derived growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Three isoforms of platelet-derived growth factors all have the capability to induce angiogenesis in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Platelet-Derived Growth Factor is AngiogenicIn Vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

PDGF BB induces VEGF secretion in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Sunitinib: from rational design to clinical efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Modes of resistance to anti-angiogenic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Basic fibroblast growth factor and receptor expression in human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Basic fibroblast growth factor and its receptor messenger ribonucleic acids are expressed in human ovarian epithelial neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Expression of fibroblast growth factor (FGF)-8 isoforms and FGF receptors in human ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.035

10.1016/J.YGYNO.2010.11.035

7 January 2021

Identifiers

DOI

1 reference

23 August 2017

1 reference